Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Avenue Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 8 | 7 | −1 |
| Shares | 197.5K | 192.6K | −4.89K (−2.5%) |
| Value | $491.8K | $385.3K | −$106.6K (−21.7%) |
New holders (3)
Institutions that held Avenue Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ikarian Capital, LLC | 140,000 | $280.0K | 0.08% |
| Boothbay Fund Management, LLC | 41,089 | $82.2K | 0.00% |
| SBI Securities Co., Ltd. | 9 | $18 | 0.00% |
Sold out (4)
Institutions that held Avenue Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Armistice Capital, LLC | 115,000 | $286.4K |
| Sabby Management, LLC | 63,060 | $157.0K |
| Moss Adams Wealth Advisors LLC | 11,000 | $27.4K |
| JPMorgan Chase & Co | 1 | $3 |